desmoglein 3 Inhibitors
Desmoglein 3 inhibitors encompass a group of chemical compounds that can directly or indirectly reduce the activity or expression of desmoglein 3, a crucial desmosomal cadherin involved in cell-cell adhesion in epithelial tissues. The inhibitors listed here are primarilykinase inhibitors, which act on various key signaling pathways known to modulate desmoglein 3 function and stability indirectly. These inhibitors do not target desmoglein 3 directly, but act on upstream signaling molecules that influence the phosphorylation status of desmoglein 3. For instance, Gefitinib and Erlotinib are EGFR inhibitors that disrupt the EGFR pathway's modulation of desmoglein 3 phosphorylation, leading to alterations in the protein's stability and function. Similarly, Sorafenib, a multi-kinase inhibitor, targets the RAF kinases within the ERK pathway, which can also modulate desmoglein 3 phosphorylation status. Sunitinib, on the other hand, inhibits VEGF receptors, which are part of pathways influencing desmoglein 3's stability and performance.
Another class of desmoglein 3 inhibitors involves mTOR and protein kinase inhibitors, like Rapamycin and Staurosporine. These inhibitors disrupt the mTOR pathway and PKC-mediated pathways, respectively, both of which can influence the phosphorylation status of desmoglein 3, thereby altering its stability and function. Dasatinib, a multi-kinase inhibitor, targets Src family kinases, which are known to modulate desmoglein 3 phosphorylation. Meanwhile, Imatinib targets BCR-ABL tyrosine kinases, which also have a role in the modulation of desmoglein 3 phosphorylation. Finally, the group includes MEK and PI3K inhibitors, such as Trametinib, U0126, LY294002, and Wortmannin. These inhibitors act on the MEK and PI3K pathways, both of which can influence the phosphorylation status and, therefore, the stability and function of desmoglein 3. By inhibiting these pathways, these compounds can lead to a reduction in desmoglein 3 stability and function. Together, these inhibitors represent a broad spectrum of chemical compounds capable of modulating desmoglein 3 indirectly via various biochemical pathways.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR). The EGFR pathway can influence the stability and function of desmoglein 3 by modulating its phosphorylation status. By inhibiting EGFR, gefitinib disrupts this pathway, potentially leading to reduced stability and function of desmoglein 3. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib is another EGFR inhibitor. By inhibiting EGFR, it disrupts the EGFR pathway and its modulation of desmoglein 3 phosphorylation, potentially leading to reduced stability and function of desmoglein 3. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a multi-kinase inhibitor that targets RAF kinases. RAF is part of the ERK pathway, which can influence desmoglein 3 function by modulating its phosphorylation status. By inhibiting RAF kinases, sorafenib disrupts this pathway, potentially leading to reduced stability and function of desmoglein 3. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib is a multi-kinase inhibitor that targets VEGF receptors. These receptors are part of pathways that can influence the stability and function of desmoglein 3. By inhibiting VEGF receptors, sunitinib disrupts these pathways, potentially leading to reduced stability and function of desmoglein 3. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is a mTOR inhibitor. The mTOR pathway can influence the stability and function of desmoglein 3 by modulating its phosphorylation status. By inhibiting mTOR, rapamycin disrupts this pathway, potentially leading to reduced stability and function of desmoglein 3. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases, including PKC. PKC can influence the stability and function of desmoglein 3 by modulating its phosphorylation status. By inhibiting PKC, staurosporine disrupts this pathway, potentially leading to reduced stability and function of desmoglein 3. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a multi-kinase inhibitor that targets Src family kinases. Src kinases can influence the stability and function of desmoglein 3 by modulating its phosphorylation status. By inhibiting Src kinases, dasatinib disrupts this pathway, potentially leading to reduced stability and function of desmoglein 3. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib is a BCR-ABL tyrosine kinase inhibitor. ABL kinases can influence the stability and function of desmoglein 3 by modulating its phosphorylation status. By inhibiting ABL kinases, imatinib disrupts this pathway, potentially leading to reduced stability and function of desmoglein 3. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib is a MEK inhibitor. The MEK pathway can influence the stability and function of desmoglein 3 by modulating its phosphorylation status. By inhibiting MEK, trametinib disrupts this pathway, potentially leading to reduced stability and function of desmoglein 3. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor. The PI3K pathway can influence the stability and function of desmoglein 3 by modulating its phosphorylation status. By inhibiting PI3K, LY294002 disrupts this pathway, potentially leading to reduced stability and function of desmoglein 3. | ||||||